Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Argenica Therapeutics Ltd ( (AU:AGN) ).
Argenica Therapeutics has announced significant findings from a preclinical study indicating that their neuroprotective candidate, ARG-007, effectively reduces axonal injury and neuroinflammation in cases of moderate traumatic brain injury (TBI) in rats. These results suggest that ARG-007 could play a crucial role in preventing the acute and chronic consequences of TBI, potentially positioning the company as a leader in TBI therapeutic interventions.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Limited is a biotechnology company focused on developing novel therapeutics to mitigate brain tissue death following strokes, brain injuries, and neurodegenerative diseases. Their lead candidate, ARG-007, is a neuroprotective peptide that has shown promise in preclinical models for stroke, traumatic brain injury (TBI), and hypoxic ischaemic encephalopathy (HIE). The company is currently engaged in Phase 2 clinical trials for acute ischaemic stroke patients.
YTD Price Performance: 11.11%
Average Trading Volume: 113,059
Technical Sentiment Consensus Rating: Sell
Learn more about AGN stock on TipRanks’ Stock Analysis page.
